Kinnevik AB (0RH1.L): BCG Matrix [Apr-2026 Updated]

Kinnevik's portfolio is a study in active capital allocation: high-growth software and health "Stars" like Spring Health, TravelPerk, Mews and Pleo are being fueled to scale, a healthy SEK 8.6bn net cash "war chest" and steady cash generators like Betterment and Cityblock underwrite that push, while capital‑intensive Question Marks (Aira, Enveda, Stegra, Tandem) demand follow‑on investment to prove market leadership and legacy Dogs are being culled to free resources-a concentrated strategy that will determine whether Kinnevik converts momentum into lasting value.

Kinnevik AB (0RH1.L) - BCG Matrix Analysis: Stars

Stars within Kinnevik's portfolio are high-growth businesses with strong relative market share that demand continued capital to sustain expansion. As of December 2025, Kinnevik's Star cluster is led by Spring Health, TravelPerk, Mews and Pleo, which together represent a substantial portion of portfolio value and revenue momentum, while operating in large addressable markets and demonstrating improving unit economics.

The table below summarizes key financial and operational metrics for each Star as of December 2025, and shows portfolio weight, fair value, revenue run-rates, growth rates and margin trends.

Collectively, these Stars account for 46 percent of Kinnevik's portfolio value (18% + 15% + 6% + 7% = 46%), representing SEK 13.4bn in fair value (SEK 5.3bn + SEK 4.4bn + SEK 1.7bn + SEK 2.0bn = SEK 13.4bn) and material revenue run-rates (TravelPerk USD 275m; Mews EUR 330m; Spring Health and Pleo high growth trajectories).

Primary strategic implications for the Star cluster:

• Continued capital allocation to sustain market share capture and support product expansion.
• Focus on accelerating path to profitability where near-term breakeven is achievable (e.g., Spring Health).
• Support margin expansion initiatives (e.g., TravelPerk's margin improvement, Mews' scalable platform economics, Pleo's enterprise product monetization).
• Prepare exit readiness where public or strategic market windows are viable (e.g., TravelPerk IPO potential in 2026).

Funding and value-creation activities observed in 2025 include participation in large financing rounds (TravelPerk USD 200m round, Mews EUR 70m round) and targeted secondary investments to protect and grow Kinnevik's equity stake while enabling companies to scale internationally and deepen product suites.

Operational KPIs underpinning Star performance include contract scale and coverage (Spring Health: 450 contracts, 20M+ covered lives), revenue run-rates and ARR trajectories (TravelPerk USD 275m; Mews EUR 330m), and consistent percentage-point margin improvements across EBITDA and gross margins (TravelPerk +30pp gross margin improvement since 2022; Mews +4pp EBITDA; Pleo +2pp margin).

Kinnevik AB (0RH1.L) - BCG Matrix Analysis: Cash Cows

Cash Cows

Kinnevik's net cash position is the primary liquidity engine for the group. As of December 2025 the company reports net cash of SEK 8.6bn, built predominantly from the Tele2 divestment that generated gross proceeds in excess of SEK 13.0bn. The SEK 8.6bn net cash balance constitutes approximately 23% of Kinnevik's reported Net Asset Value (NAV) of SEK 37.5bn and supports a low-leverage capital structure with minimal external borrowing requirements.

The cash position functions as the "cash cow" for Kinnevik's portfolio, enabling follow-on capital to higher-growth Stars and to selected Question Marks while preserving balance sheet optionality. This reduces reliance on external capital markets and preserves financial flexibility for opportunistic M&A, share buybacks or special dividends.

• Primary uses of cash: capital injections into Star/Question Mark assets, opportunistic acquisitions, and capital returns to shareholders.
• Balance sheet strength metric: net cash/ NAV = 23% provides a sizable war chest vs. peers in the Nordic investment trust cohort.
• Risk mitigation: lower refinancing risk and capacity to withstand macro shocks without forced disposals.

Betterment operates as a stable, lower-growth cash-generating asset within Kinnevik's financial services exposure. Betterment is valued at SEK 1.7bn (approximately 6% of total portfolio value) as of late 2025. The business sits in a mature robo-advisory market and has pivoted toward profitability, contributing to an improvement of roughly 2 percentage points in the group's average EBITDA margin. The business's mature unit economics and constrained incremental capital needs make it a predictable income contributor and a classic cash cow in portfolio management terms.

Cityblock Health is a maturing asset within Kinnevik's healthcare allocation and functions as a complementary cash cow. Valued also at SEK 1.7bn (circa 6% of portfolio) as of end-2025, Cityblock's strategy has shifted from rapid expansion to operational efficiency and near-term self-funding. The business focuses on Medicaid and dual-eligible populations - a relatively stable, lower-growth segment compared with Kinnevik's Star digital consumer assets. Kinnevik expects Cityblock to contribute to a collective breakeven across core investments by early 2026.

Collective financial impact of cash cows:

• Combined fair value (Betterment + Cityblock): SEK 3.4bn (≈12% of portfolio).
• Net cash + cash cow holdings provide immediate funding capacity: SEK 12.0bn total (SEK 8.6bn net cash + SEK 3.4bn cash-cow fair value).
• Effect on capital allocation: enables selective reinvestment into Stars and coverage of operating cash shortfalls without new debt issuance.

Kinnevik AB (0RH1.L) - BCG Matrix Analysis: Question Marks

Dogs - Question Marks

Aira represents a high-potential entry into the rapidly growing European clean energy technology market. As of December 2025 Aira has reached an annual run-rate sales figure of EUR 200m and accounts for 4% of Kinnevik's portfolio value. Kinnevik participated in a EUR 150m funding round to expand heat pump production capacity in Poland. The residential decarbonization market is growing at double-digit annual rates, yet Aira's relative market share remains low as it scales; significant CAPEX and follow-on funding are required to compete with established HVAC incumbents, placing Aira squarely in the Question Mark quadrant.

Enveda Biosciences is a high-growth venture in AI-powered drug discovery and techbio, holding 5% of Kinnevik's portfolio with a fair value of SEK 1.4bn following a USD 150m funding round in 2025. Enveda entered clinical trials with its first drug candidates - a pivotal but high-risk milestone for biotech. The underlying market is nascent with high growth rates but uncertain commercialization timelines; Kinnevik's SEK 192m investment in the 2025 round is a strategic bet on Enveda's ability to translate AI-led discovery into approved therapeutics and market share.

Stegra (formerly H2 Green Steel) is a capital-intensive green industrial project, representing 4% of portfolio value at SEK 1.3bn as of late 2025. The business is in the construction phase of a large-scale green steel plant and requires massive CAPEX and recurring financing rounds. Market demand for low-carbon steel is expected to surge under tightening carbon regulations, but Stegra's current market share is effectively zero because commercial production has not yet commenced; execution risk and future price spreads for low-carbon products determine its prospects.

Tandem Health is a new early-stage addition focusing on AI-driven healthcare infrastructure. Kinnevik led a EUR 40m funding round in mid-2025, investing SEK 333m for a minority stake. Tandem pioneers clinical workflows using generative AI in a market still in its infancy with high growth potential. As a recent investment Tandem has a low relative market share and must validate commercial viability; it is a classic Question Mark where early capital aims to capture future market leadership if product-market fit and regulatory acceptance align.

Strategic considerations for these Question Marks:

• Follow-on capital: prioritize companies with clear path-to-scale and unit economics (Aira, Stegra require staged CAPEX; Enveda and Tandem require milestone-linked funding).
• Milestone gating: tie future investments to production ramp, regulatory readouts, or commercial contracts to limit downside.
• Partnerships & offtake: secure industrial offtake or distribution partnerships (Stegra and Aira) to de-risk demand and improve valuation visibility.
• Exit flexibility: maintain optionality for sale, IPO, or dilution-protected follow-ons depending on progress; monitor valuations vs. required capital intensity.
• Operational support: provide board-level guidance, recruitment, and commercial introductions to accelerate market share gains in double-digit growth segments.

Kinnevik AB (0RH1.L) - BCG Matrix Analysis: Dogs

Non-core financial services investments classified as 'Dogs' have been systematically divested due to low market growth and negligible relative market share. In early 2025 Kinnevik announced a portfolio transaction releasing capital from three such assets-Sure, Lunar and XYB-with expected gross proceeds of EUR 65.5m. These assets were sold at discounts to prior fair value and operated in crowded, low-margin markets where they failed to achieve scale. The transaction aligns with Kinnevik's explicit strategy to exit Dog positions and redeploy capital toward higher-return segments (vertical software and health-tech).

Monese remains illustrative of Dog-category dynamics in the European neobanking space. As of late 2025 Monese is classified within the 'Other' segment-an aggregation that constitutes 27% of Kinnevik's portfolio by value but comprises many smaller, underperforming assets. Monese has experienced material valuation write-downs versus earlier carrying values after failing to keep pace with category leaders (e.g., Revolut, Monzo). Operating metrics point to low organic growth rates (single-digit percentage CAGR), depressed unit economics and persistently negative EBITDA margins, making Monese a candidate for further divestment or write-off rather than a path to Star status.

VillageMD represents a material Dog example that drove adverse portfolio performance. The investment was a major detractor leading to a substantial write-off in 2024 and was largely exited or written down by December 2025. The VillageMD exposure was a principal cause of an approximate 11% decline in the private portfolio value during the prior fiscal year. Any residual holding is categorized as a Dog due to persistent failure to meet targeted growth and margin metrics. Kinnevik reports that 73% of the portfolio is now profitable or funded to breakeven, implying VillageMD-type positions are being minimized.

Legacy marketplace investments that failed to transition to the new growth model continue to be phased out. These smaller holdings within the SEK 8.1bn 'Other' segment typically show low single-digit revenue growth and negative EBITDA, and are being managed for liquidity rather than strategic scale. The rebalancing objective is clear: concentrate capital into vertical software and health-tech, increasing core company exposure from 29% (2024) to 54% (late 2025) while reducing the weight of legacy Dogs.

• Divestment actions: portfolio sales (Sure, Lunar, XYB) generating EUR 65.5m gross proceeds (Q1 2025).
• Write-downs: material impairments taken in 2024-2025 (notably VillageMD) leading to ~11% private portfolio contraction in FY2024.
• Portfolio concentration target: shift from 29% core (2024) to 54% core (Dec 2025); manage remaining 46% legacy for liquidity.
• Monitoring criteria for Dogs: sub‑10% revenue CAGR, negative EBITDA margins, persistent market-share erosion.

Operationally, these Dog-classified assets are treated as non-core: prioritized for sale or wind-down, valued conservatively with frequent impairment testing, and excluded from long-term reinvestment plans. Capital redeployment focuses on higher-growth Stars and potential Cash Cows within Kinnevik's chosen verticals.